{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:55:46Z","timestamp":1780548946147,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the construction fund of Shenzhen Clinical Research Center for Urology and Nephrology","award":["LCYSSQ20220823091403008"],"award-info":[{"award-number":["LCYSSQ20220823091403008"]}]},{"name":"Shenzhen High-level Hospital Construction Fund, Clinical Research Project of Peking University Shenzhen Hospital","award":["LCYJ2020002, LCYJ2020015, LCYJ2020020, LCYJ2017001"],"award-info":[{"award-number":["LCYJ2020002, LCYJ2020015, LCYJ2020020, LCYJ2017001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Computed tomography (CT) is widely used to the diagnosis of upper urinary tract epithelial tumors, but the relatively inaccurate results may affect subsequent treatment. Cystoscopy is widely used for preoperative diagnosis of bladder tumors and postoperative review of urothelial carcinoma, but its invasiveness and corresponding complications are feared by patients. There is an urgent need to find a convenient, cost-effective and non-invasive diagnostic method to reduce the false-positive and false-negative rates of urinary tract CT, and to replace cystoscopy in the preoperative diagnosis of bladder tumors or postoperative monitoring the bladder for recurrent of urothelial carcinoma. The study aimed to evaluate the diagnostic value of YiDiXie\u2122-30, YiDiXie\u2122-32, and YiDiXie\u2122-48 in urothelial cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      439 study subjects were finally included in this study (malignant group,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009292, benign group,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200990; relapse group,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200922, relapse-free group,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200935). The remaining serum samples from the subjects were collected and tested by applying the YiDiXie\u2122 all-cancer detection kit to evaluate the sensitivity and specificity, positive likelihood ratio, and negative likelihood ratio of YiDiXie\u2122-30, YiDiXie\u2122-32, and YiDiXie\u2122-48. Receiver-operating characteristic curves\u2019 analyses were included in this study.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of YiDiXie\u2122-30 were 74.7%, 92.2%, 9.6, and 0.27, respectively. The sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of YiDiXie\u2122-32 were 86.6%, 84.4%, 5.6, and 0.16, respectively. The sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio were 96.2%, 65.6%, 2.8, and 0.06, respectively. Further studies revealed that YiDiXie\u2122-30, YiDiXie\u2122-32, and YiDiXie\u2122-48 had similar results in patients with positive or negative urothelial CT. The negative likelihood ratios of YiDiXie\u2122-30, YiDiXie\u2122-32, and YiDiXie\u2122-48 with ultrasound concurrently in the relapse and relapse-free groups were 0.05, 0.05, and 0. In the malignant and benign groups with diameters\u2009&lt;\u20092.0\u00a0cm negative likelihood ratios of YiDiXie\u2122-30.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>YiDiXie\u2122 tests showed considerable validity in the diagnosis of urothelial carcinoma with significantly different levels of sensitivity and specificity. They have significant diagnostic value in urothelial carcinoma, improving the diagnosis of upper urinary tract epithelial tumors and potentially providing an alternative to cystoscopy in combination with CT or ultrasound.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Clinical study registration number<\/jats:italic>\n                      ChiCTR2200066840.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40001-025-03369-7","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:20:14Z","timestamp":1762957214000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of the diagnostic performance of YiDiXie\u2122 tests in urothelial carcinoma"],"prefix":"10.1186","volume":"30","clinical-trial-number":[{"clinical-trial-number":"chictr2200066840","registry":"10.18810\/chictr"}],"author":[{"given":"Huimei","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjian","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenkang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xionghui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqing","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"1","key":"3369_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","volume":"84","author":"M Roupr\u00eat","year":"2023","unstructured":"Roupr\u00eat M, Seisen T, Birtle AJ, Capoun O, Comp\u00e9rat EM, Dominguez-Escrig JL, et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 update. Eur Urol. 2023;84(1):49\u201364. https:\/\/doi.org\/10.1016\/j.eururo.2023.03.013.","journal-title":"Eur Urol"},{"issue":"4","key":"3369_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.eururo.2010.12.042","volume":"59","author":"M Roupr\u00eat","year":"2011","unstructured":"Roupr\u00eat M, Zigeuner R, Palou J, Boehle A, Kaasinen E, Sylvester R, et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol. 2011;59(4):584\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2010.12.042.","journal-title":"Eur Urol"},{"issue":"1","key":"3369_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"3369_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"3369_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"3369_CR6","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1097\/ju.0000000000003480","volume":"209","author":"JA Coleman","year":"2023","unstructured":"Coleman JA, Clark PE, Bixler BR, Buckley DI, Chang SS, Chou R, et al. Diagnosis and management of non-metastatic upper tract urothelial carcinoma: AUA\/SUO guideline. J Urol. 2023;209(6):1071\u201381. https:\/\/doi.org\/10.1097\/ju.0000000000003480.","journal-title":"J Urol"},{"issue":"1","key":"3369_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/ju.0000000000003981","volume":"212","author":"J Holzbeierlein","year":"2024","unstructured":"Holzbeierlein J, Bixler BR, Buckley DI, Chang SS, Holmes RS, James AC, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; amended 2020, 2024). J Urol. 2024;212(1):3\u201310. https:\/\/doi.org\/10.1097\/ju.0000000000003981.","journal-title":"J Urol"},{"issue":"4","key":"3369_CR8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/ju.0000000000003846","volume":"211","author":"JM Holzbeierlein","year":"2024","unstructured":"Holzbeierlein JM, Bixler BR, Buckley DI, Chang SS, Holmes R, James AC, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment. J Urol. 2024;211(4):533\u20138. https:\/\/doi.org\/10.1097\/ju.0000000000003846.","journal-title":"J Urol"},{"issue":"6","key":"3369_CR9","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/cncr.24135","volume":"115","author":"V Margulis","year":"2009","unstructured":"Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009;115(6):1224\u201333. https:\/\/doi.org\/10.1002\/cncr.24135.","journal-title":"Cancer"},{"issue":"6","key":"3369_CR10","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/ajco.14001","volume":"19","author":"H Gurney","year":"2023","unstructured":"Gurney H, Clay TD, Oliveira N, Wong S, Tran B, Harris C. Systemic treatment of advanced and metastatic urothelial cancer: the landscape in Australia. Asia-Pac J Clin Oncol. 2023;19(6):585\u201395. https:\/\/doi.org\/10.1111\/ajco.14001.","journal-title":"Asia-Pac J Clin Oncol"},{"key":"3369_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232214319","author":"H Pakmanesh","year":"2022","unstructured":"Pakmanesh H, Anvari O, Forey N, Weiderpass E, Malekpourafshar R, Iranpour M, et al. TERT promoter mutations as simple and non-invasive urinary biomarkers for the detection of urothelial bladder cancer in a high-risk region. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms232214319.","journal-title":"Int J Mol Sci"},{"issue":"18","key":"3369_CR12","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/bf03262330","volume":"21","author":"MF Botteman","year":"2003","unstructured":"Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003;21(18):1315\u201330. https:\/\/doi.org\/10.1007\/bf03262330.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"3369_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Dominguez Escrig JL, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81(1):75\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.010.","journal-title":"Eur Urol"},{"issue":"4","key":"3369_CR14","doi-asserted-by":"publisher","first-page":"216","DOI":"10.6004\/jnccn.2024.0024)","volume":"22","author":"TW Flaig","year":"2024","unstructured":"Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK, et al. NCCN guidelines\u00ae insights: bladder cancer, version 32024. J Nat Comprehens Cancer Netw. 2024;22(4):216\u201325. https:\/\/doi.org\/10.6004\/jnccn.2024.0024).","journal-title":"J Nat Comprehens Cancer Netw."},{"issue":"2","key":"3369_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/bju.13652","volume":"119","author":"A Grahn","year":"2017","unstructured":"Grahn A, Melle-Hannah M, Malm C, J\u00e4derling F, Radecka E, Beckman M, et al. Diagnostic accuracy of computed tomography urography and visual assessment during ureterorenoscopy in upper tract urothelial carcinoma. BJU Int. 2017;119(2):289\u201397. https:\/\/doi.org\/10.1111\/bju.13652.","journal-title":"BJU Int"},{"issue":"3","key":"3369_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/bf02549531","volume":"24","author":"M Pavone-Macaluso","year":"1992","unstructured":"Pavone-Macaluso M, Lamartina M, Pavone C, Vella M. The flexible cystoscope. Int Urol Nephrol. 1992;24(3):239\u201342. https:\/\/doi.org\/10.1007\/bf02549531. (Vella).","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"3369_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s41747-019-0126-1","volume":"3","author":"MV Chan","year":"2019","unstructured":"Chan MV, McDonald SJ, Ong YY, Mastrocostas K, Ho E, Huo YR, et al. Hcc screening: assessment of an abbreviated non-contrast MRI protocol. Eur Radiol Exp. 2019;3(1):49. https:\/\/doi.org\/10.1186\/s41747-019-0126-1.","journal-title":"Eur Radiol Exp"},{"issue":"3","key":"3369_CR18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s11547-011-0623-z","volume":"116","author":"P Martingano","year":"2011","unstructured":"Martingano P, Stacul F, Cavallaro MF, Cernic S, Bregant P, Cova MA. 64-slice CT urography: optimisation of radiation dose. Radiol Med. 2011;116(3):417\u201331. https:\/\/doi.org\/10.1007\/s11547-011-0623-z.","journal-title":"Radiol Med"},{"issue":"1","key":"3369_CR19","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1148\/radiol.2321030222","volume":"232","author":"RD Nawfel","year":"2004","unstructured":"Nawfel RD, Judy PF, Schleipman AR, Silverman SG. Patient radiation dose at CT urography and conventional urography. Radiology. 2004;232(1):126\u201332. https:\/\/doi.org\/10.1148\/radiol.2321030222.","journal-title":"Radiology"},{"issue":"7","key":"3369_CR20","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.3174\/ajnr.A4615","volume":"37","author":"J Ramalho","year":"2016","unstructured":"Ramalho J, Semelka RC, Ramalho M, Nunes RH, AlObaidy M, Castillo M. Gadolinium-based contrast agent accumulation and toxicity: an update. AJNR Am J Neuroradiol. 2016;37(7):1192\u20138. https:\/\/doi.org\/10.3174\/ajnr.A4615.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"5","key":"3369_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/rli.0000000000000273","volume":"51","author":"VM Runge","year":"2016","unstructured":"Runge VM. Safety of the gadolinium-based contrast agents for magnetic resonance imaging, focusing in part on their accumulation in the brain and especially the dentate nucleus. Invest Radiol. 2016;51(5):273\u20139. https:\/\/doi.org\/10.1097\/rli.0000000000000273.","journal-title":"Invest Radiol"},{"key":"3369_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw205","author":"CK Altice","year":"2016","unstructured":"Altice CK, Banegas MP, Tucker-Seeley RD, Yabroff KR. Financial hardships experienced by cancer survivors: a systematic review. J Natl Cancer Inst. 2016. https:\/\/doi.org\/10.1093\/jnci\/djw205.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"3369_CR23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1464-410X.2011.10664.x","volume":"110","author":"CG Blick","year":"2012","unstructured":"Blick CG, Nazir SA, Mallett S, Turney BW, Onwu NN, Roberts IS, et al. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic. BJU Int. 2012;110(1):84\u201394. https:\/\/doi.org\/10.1111\/j.1464-410X.2011.10664.x.","journal-title":"BJU Int"},{"issue":"4","key":"3369_CR24","doi-asserted-by":"publisher","first-page":"412","DOI":"10.5301\/tj.5000331","volume":"101","author":"E Capalbo","year":"2015","unstructured":"Capalbo E, Kluzer A, Peli M, Cosentino M, Berti E, Cariati M. Bladder cancer diagnosis: the role of CT urography. Tumori. 2015;101(4):412\u20137. https:\/\/doi.org\/10.5301\/tj.5000331.","journal-title":"Tumori"},{"issue":"3","key":"3369_CR25","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00261-017-1249-6","volume":"43","author":"TW Trinh","year":"2018","unstructured":"Trinh TW, Glazer DI, Sadow CA, Sahni VA, Geller NL, Silverman SG. Bladder cancer diagnosis with CT urography: test characteristics and reasons for false-positive and false-negative results. Abdominal Radiol. 2018;43(3):663\u201371. https:\/\/doi.org\/10.1007\/s00261-017-1249-6.","journal-title":"Abdominal Radiol"},{"issue":"2","key":"3369_CR26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J Clin. 2017;67(2):93\u20139. https:\/\/doi.org\/10.3322\/caac.21388.","journal-title":"CA Cancer J Clin"},{"issue":"21","key":"3369_CR27","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1002\/sim.2164","volume":"24","author":"SA Julious","year":"2005","unstructured":"Julious SA. Two-sided confidence intervals for the single proportion: comparison of seven methods by Robert G. Newcombe, Statistics in Medicine 1998;17:857\u2013872. Stat Med. 2005;24(21):3383\u20134. https:\/\/doi.org\/10.1002\/sim.2164.","journal-title":"Stat Med"},{"issue":"3","key":"3369_CR28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/s0004-9514(14)60228-2","volume":"48","author":"M Davidson","year":"2002","unstructured":"Davidson M. The interpretation of diagnostic test: a primer for physiotherapists. Austral J Physiother. 2002;48(3):227\u201332. https:\/\/doi.org\/10.1016\/s0004-9514(14)60228-2.","journal-title":"Austral J Physiother"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03369-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03369-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03369-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:20:16Z","timestamp":1762957216000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-03369-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3369"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03369-7","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"15 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol of this study was approved by the Ethics Committee of Peking University Shenzhen Hospital. All participants recruited in our study provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that there are no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1113"}}